

# CERTIFICATE OF PHARMACEUTICAL PRODUCT<sup>1</sup>

This certificate conforms to the format recommended by the World Health Organization  
(General instructions and explanatory notes attached)

No. of certificate : DCA/DML/KPL/2024/070

VALID UPTO: 27.12.2025

Exporting (certifying) country : INDIA  
Importing (requesting) country : UKRAINE

1. Name and dosage form of product : CICLOFAMID (Cyclophosphamide for Injection BP 200mg/vial)

1.1 Active ingredient(s)<sup>2</sup> and amount(s) per unit dose<sup>3</sup> :

**Composition:**

Each vial contains:

Cyclophosphamide BP equivalent to

Anhydrous Cyclophosphamide 200 mg

For complete qualitative composition including excipients, see attached.<sup>4</sup> NA

1.2 Is this product licensed to be placed on the market for use in the exporting country?<sup>5</sup> Yes ☒ No ☐

1.3 Is this product actually on the market in the exporting country? Yes ☒ No ☐ Unknown ☐

If the answer to 1.2 is Yes, continue with section 2A and omit section 2B

If the answer to 1.2 is No, omit section 2A continue section 2B<sup>6</sup>

## 2A

A.1 Number of product license<sup>7</sup> NNZ/08/40 & BNZ/08/41  
and date of issue : 28.12.2020

A.2 Product license holder: KWALITY PHARMACEUTICALS LTD.  
(Name and address) 1-A, Industrial Area, Raja Ka Bagh  
Teh: Nurpur, Distt: Kangra (H.P.)  
PIN: 176201

A.3 Status of product license Holder<sup>8</sup>

a ☒ b ☐ c ☐

A3.1 For categories b and c the name and address of the  
Manufacturer producing the dosage  
form are<sup>9</sup> : Not Applicable

A.4 Is summary basis of approval appended ?<sup>10</sup>

Yes ☐ No ☒

A.5 Is the attached, officially approved product information  
Complete and consonant with the license ?<sup>11</sup>

Yes ☐ No ☐ Not provided ☒

A.6 Application for certificate if different from  
license holder<sup>12</sup> : Not Applicable

## 2B

B.1 Applicant for certificate (name and address)

B.2 Status of application:

a ☐ b ☐ c ☐ d ☐

B.2.1 For categories b and c the name and address of the  
manufacturer producing the dosages form are<sup>9</sup>

B.3 Why is marketing authorization lacking

☐ ☐ ☐ ☐

Not Not under  
Required Requested consideration

B.4 Remark :<sup>13</sup>

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced?

Yes ☒ No ☐ Not applicable<sup>14</sup> ☐

If no or not applicable proceed to question 4

3.1 Periodicity of routine inspections (years): Once in a Year

3.2 Has the manufacture of this type of dosage form been inspected? Yes ☒ No ☐

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organisation?<sup>15</sup>

Yes ☒ No ☐ Not applicable ☐

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?<sup>16</sup>

Yes ☒ No ☐ Not applicable ☐

If no, explain:

Address of certifying authority:  
Assistant Drugs Controller,  
cum- Licensing Authority,  
O/o State Drugs Controller  
Baddi, Distt. Solan, H.P. 173205  
01795-244288, sdc4hp@gmail.com



Name of the Authorized Person: Dr. Kamlesh Naik

Signature:   
Stamp and date:   
Cum Licensing Authority  
O/o State Drugs Controller  
Baddi, Distt. Solan, H.P.173205

sdc4hp@gmail.com, 01795-244288

18 OCT 2024



## GENERAL INSTRUCTION:

Please refer to the guidelines for full instruction on how to complete this form and information on the implementation of the scheme. The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than hand written. Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

## EXPLANATORY NOTES:

1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
2. Use, whenever possible, International Nonproprietary Names (INNS) or national nonproprietary names.
3. The formula (complete composition) of the dosage form should be given on the certificate or be appended.
4. Details of quantitative composition are preferred, but their provision is subject to the agreement of the product License holder. 5. When applicable, append details of any restriction applied to the sale, distribution, or administration of the product that is specified in the product License.
6. Sections 2A and 2B are mutually exclusive.
7. Indicate, when applicable, if the License is provisional, or the product has not yet been approved.
8. Specify whether the person responsible for placing the product on the market:
  - (a) Manufactures the dosages form
  - (b) Packages and / or labels a dosage form manufactured by an independent company: or
  - (c) is involved in none of the above .
9. This information can be provided only with the consent of the product - License holder or, in the case of nonregistered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product License. If the production site is changed the License must be updated or it will cease to be valid.
10. This refers to the document, prepared by some national regulatory authorities, that summarizes the on which the product has been licensed.
11. This refers to product information approved by the competent national regulatory authority, such as a summary of product characteristics (SPC).
12. In this circumstance, permission for issuing the certificate is required from the product License holder. This permission must be provided to the authority by the applicant.
13. Please indicate the reason that the applicant has provided for not requesting registration:
  - (a) the product has been developed exclusively for the treatment of conditions – particularly tropical diseases – not endemic in the country of export:
  - (b) the product has been reformulated with a view to improving its stability under tropical conditions:
  - (c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import:
  - (d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient
  - (e) any other reason, please specify.
14. Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
15. The requirements for good practices in the manufacture and quality control of drugs referred to the certificate are those included in the thirty- second report of the Expert Committee on specifications for Pharmaceutical Preparations (WHO Technical Report Series, No.823 , 1992 , Annex 1) Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series , No . 822, 1992, Annex 1).
16. The Section is to be completed when the product - license holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form and the extent and nature of any controls exercised over each of these parties.

*The layout for this Model Certificate is available on diskette in Word Perfect from the Division of Drug Management and Policies. World Health Organization, 1211 Geneva 27, Switzerland.*